Methadone and perinatal outcomes: A prospective cohort study

Addiction

Volumn 107, Issue 8, 2012, Pages 1482-1492

  Cleary, Brian J ^a,b,c   Eogan, Maeve ^d   O'Connell, Michael P ^a   Fahey, Tom ^b   Gallagher, Paul J ^b   Clarke, Tom ^d   White, Martin J ^a   McDermott, Christine ^d   O'Sullivan, Anne ^a   Carmody, Deirdre ^e   Gleeson, Justin ^e   Murphy, Deirdre J ^a,c  

^a Molecular Pathology Laboratory   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d ROTUNDA HOSPITAL   (Ireland)

^e HEALTH SERVICE EXECUTIVE   (Ireland)

Author keywords

Methadone; Neonatal abstinence syndrome; Pregnancy; Small for gestational age; Withdrawal

Indexed keywords

BENZODIAZEPINE DERIVATIVE; METHADONE; NARCOTIC AGENT;

ADULT; ARTICLE; CANNABIS ADDICTION; DOSE RESPONSE; FEMALE; HEROIN DEPENDENCE; HUMAN; METHODOLOGY; NEWBORN; NEWBORN INTENSIVE CARE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRENATAL CARE; PROSPECTIVE STUDY; SMALL FOR DATE INFANT; STATISTICS; WITHDRAWAL SYNDROME;

ADULT; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEROIN DEPENDENCE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; INTENSIVE CARE, NEONATAL; MARIJUANA ABUSE; METHADONE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL CARE; PROSPECTIVE STUDIES;

EID: 84863772098     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.03844.x     Document Type: Article

References (51)

1. European Monitoring Centre for Drugs and Drug Addiction. Trends in Injecting Drug Use in Europe. Lisbon: Publications Office of the European Union; 2010.
2. Dryden C., Young D., Hepburn M., Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. Br J Obstet Gynaecol 2009; 116: 665-71.
3. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-51.
4. Department of Health (England), the Scottish Government, Welsh Assembly Government, Northern Ireland Executive. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London; Department of Health (England), the Scottish Government, Welsh Assembly Government, Northern Ireland Executive; 2007.
5. Finnegan L. P. Management of pregnant drug-dependent women. Ann NY Acad Sci 1978; 311: 135-46.
6. Cleary B. J., Donnelly J. M., Strawbridge J. D., Gallagher P. J., Fahey T., White M. J. etal. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204: 139.e1-9.
7. Jansson L. M., Svikis D. S., Velez M., Fitzgerald E., Jones H. E. The impact of managed care on drug-dependent pregnant and postpartum women and their children. Subst Use Misuse 2007; 42: 961-74.
8. Doberczak T. M., Kandall S. R., Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991; 118: 933-7.
9. Maas U., Kattner E., Weingart-Jesse B., Schafer A., Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990; 18: 111-8.
10. Madden J. D., Chappel J. N., Zuspan F., Gumpel J., Mejia A., Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977; 127: 199-201.
11. Jones H. E., O'Grady K. E., Malfi D., Tuten M. Methadone maintenance versus methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372-86.
12. Burns L., Mattick R. P., Lim K., Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 2007; 102: 264-70.
13. Cleary B. J., Donnelly J., Strawbridge J. D., Gallagher P. J., Fahey T., Clarke M. etal. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010; 105: 2071-84.
14. Kuschel C. A., Austerberry L., Cornwell M., Couch R., Rowley R. S. H. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2004; 89: F390-3.
15. Berghella V., Lim P. J., Hill M. K., Cherpes J., Chennat J., Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189: 312-7.
16. Stimmel B., Goldberg J., Reisman A., Murphy R. J., Teets K. Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used. Am J Drug Alcohol Abuse 1982; 9: 383-95.
17. Kandall S. R., Albin S., Gartner L. M., Lee K. S., Eidelman A., Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1: 159-69.
18. Arlettaz R., Kashiwagi M., Das-Kundu S., Fauchere J. C., Lang A., Bucher H. U. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005; 84: 145-50.
19. Dashe J. S., Sheffield J. S., Olscher D. A., Todd S. J., Jackson G. L., Wendel G. D. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100: 1244-9.
20. Dawe S., Gerada C., Strang J. Establishment of a liaison service for pregnant opiate-dependent women. Br J Addict 1992; 87: 867-71.
21. Harper R. G., Solish G., Feingold E., Gersten-Woolf N. B., Sokal M. M. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977; 129: 417-24.
22. Winklbaur B., Baewert A., Jagsch R., Rohrmeister K., Metz V., Aeschbach Jachmann C. etal. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009; 15: 150-6.
23. Choo R. E., Huestis M. A., Schroeder J. R., Shin A. S., Jones H. E. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75: 253-60.
24. ter Horst P. G. J., Jansman F. G. A., van Lingen R. A., Smit J. P., de Jong-van den Berg L., Brouwers J. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv 2008; 63: 267-79.
25. Seligman N. S., Salva N., Hayes E. J., Dysart K. C., Pequignot E. C., Baxter J. K. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199: 396.e1-7.
26. LaGasse L. L., Seifer R., Lester B. M. Interpreting research on prenatal substance exposure in the context of multiple confounding factors. Clin Perinatol 1999; 26: 39-54, vi.
27. Aylward G. P. Methadone outcome studies: is it more than the methadone? J Pediatr 1982; 101: 214-5.
28. Scully M., Geoghegan N., Corcoran P., Tiernan M., Keenan E. Specialized drug liaison midwife services for pregnant opioid dependent women in Dublin, Ireland. J Subst Abuse Treat 2004; 26: 329-35.
29. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. etal. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
30. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27.
31. Finnegan L. P., Ehrlich S. Maternal drug use during pregnancy: evaluation and pharmacotherapy for neonatal abstinence. In: Adler M. W., Cowan A., editors. Modern Methods in Pharmacology: Testing and Evaluation of Drugs of Abuse. New York: Wiley-Liss, Inc.; 1990, p. 255-63.
32. Gardosi J., Francis A. Customised Weight Centile Calculator-GROW-Centile. v6.4: Gestation Network. 2009. Available at:. Archived at: on 20 May 2010.
33. Royal College of Paediatrics and Child Health, Word Health Organization, Department of Health. UK-WHO Growth Charts: Early Years. London: The Royal College of Paediatrics and Child Health; 2009. Available at:. Archived at: on 24 September 2010.
34. Lim S., Prasad M. R., Samuels P., Gardner D. K., Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009; 200: 70 e1-5.
35. Liu A. J. W., Sithamparanathan S., Jones M. P., Cook C. M., Nanan R. Growth restriction in pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed 2010; 95: F258-62.
36. Hulse G. K., Milne E., English D. R., Holman C. D. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92: 1571-9.
37. Hayes E., Seligman N., Horowitz K., O'Neill M., Leiby B., Dysart K. etal. 252: Dose-response relationship between maternal methadone dose and decreased neonatal head circumference. Am J Obstet Gynecol 2007; 197: S81-S81.
38. Chasnoff I. J., Burns K. A., Burns W. J., Schnoll S. H. Prenatal drug exposure: effects on neonatal and infant growth and development. Neurobehav Toxicol Teratol 1986; 8: 357-62.
39. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-31.
40. Doberczak T. M., Kandall S. R., Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993; 81: 936-40.
41. McCarthy J. J., Leamon M. H., Parr M. S., Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005; 193: 606-10.
42. Jansson L. M., Dipietro J. A., Elko A., Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med 2007; 20: 677-85.
43. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82: 250-7.
44. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; (3): CD002208.
45. Ebner N., Rohrmeister K., Winklbaur B., Baewert A., Jagsch R., Peternell A. etal. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007; 87: 131-8.
46. Seligman N. S., Almario C. V., Hayes E. J., Dysart K. C., Berghella V., Baxter J. K. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010; 157: 428-433.e1.
47. Dunn K. E., Sigmon S. C., Reimann E. F., Badger G. J., Heil S. H., Higgins S. T. A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. Exp Clin Psychopharmacol 2010; 18: 37-50.
48. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008; 103: 1429-40.
49. Jones H. E., Haug N., Silverman K., Stitzer M., Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 2001; 61: 297-306.
50. Newman R. Response to 'Methadone Maintenance vs. Methadone Taper during Pregnancy' paper. Am J Addict 2009; 18: 250.
51. Batki S. L., Kauffman J. F., Marion I., Parrino M. W., Woody G. E., Center for Substance Abuse Treatment (CSAT). Medication-assisted treatment for opioid addiction during pregnancy. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP); no. 43. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA); 2005, p. 211-24.